ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,194 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryAllschwilBasilea Pharmaceutica International AG, Allschwil
Basilea Pharmaceutica International AG, Allschwil Logo
Verified· 3 sources

Basilea Pharmaceutica International AG, Allschwil

Summary

About the company

Basilea Pharmaceutica International AG, Allschwil develops and commercializes pharmaceutical products focused on anti-infectives, particularly antifungal and antibiotic therapies. The company’s portfolio includes Cresemba (isavuconazole) and Zevtera (ceftobiprole), and it maintains clinical and preclinical programs for additional anti-infective candidates.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered9
Development and commercialization of anti-infectives
Development and commercialization of innovative medicines in the anti-infectives area, focusing on antimycotics and antibiotics from research through to commercialization.
Antimycotics
Antimycotics for invasive fungal infections, including intravenous and oral treatments for invasive aspergillosis, mucormycosis and invasive candidiasis.
Antibiotics
Antibiotics for severe bacterial infections, in particular pneumonia, Staphylococcus aureus bacteremia, acute skin and soft tissue infections, and complicated urinary tract infections.
Cresemba (Isavuconazole)
Intravenous and oral antifungal for invasive aspergillosis and mucormycosis; marketed worldwide in many countries through license and distribution agreements.
Zevtera (Ceftobiprole)
Intravenous antibiotic for the treatment of pneumonia; in the US also approved for Staphylococcus aureus bacteremia, acute bacterial skin infections and community-acquired pneumonia.
Fosmanogepix
Clinical broad-spectrum antimycotic candidate in an intravenous and oral formulation, in Phase 2 and Phase 3 studies for candidemia and invasive fungal infections.
BAL2062
Clinical antimycotic candidate with a new mechanism of action against invasive mold infections; evaluated in a completed Phase 1 study.
Ceftibuten-ledaborbactam etzadroxil
Oral BL/BLI combination candidate with ceftibuten and ledaborbactam etzadroxil; in development for complicated urinary tract infections and not yet approved.
BAL2420 (LptA inhibitor)
Antibiotic development candidate against Gram-negative bacteria, with the first clinical study on safety, tolerability and pharmacokinetics in healthy adults.
Reviews

Aggregated rating

Aggregated rating
4.5
of 5

Aggregated from 2 reviews across all connected sources

Sources
GGoogle4.52
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Knowledge

No knowledge articles yet

Once Basilea Pharmaceutica International AG, Allschwil has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Basilea Pharmaceutica International AG, Allschwil in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Basilea Pharmaceutica International AG, Allschwil by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Basilea Pharmaceutica International AG, Allschwil to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hegenheimermattweg 167b
4123 Allschwil
Opening hours
Mon
08:00 - 12:00, 13:00 - 17:00
Tue
08:00 - 12:00, 13:00 - 17:00
Wed
08:00 - 12:00, 13:00 - 17:00
Thu
08:00 - 12:00, 13:00 - 17:00
Fri
08:00 - 12:00, 13:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-114.147.271
Founded
2008 · 18 years
Last commercial register change
July 9, 2025
Employees
101 to 500

Similar companies

BP
Bright Peak Therapeutics AG
Allschwil
IP
Idorsia Pharmaceuticals Ltd
Allschwil
PT
Palto Therapeutics AG
Allschwil
MG
MiHKAL GmbH
Allschwil
NS
Neurocrine Switzerland GmbH
Allschwil
BW
Blue Wave Therapeutics GmbH
Allschwil
IT
Ilonov Therapeutics SA
Allschwil
CT
CAPTOR THERAPEUTICS GmbH
Allschwil